etanercept vs infliximab

NCT03780959 · Phase 2/3 · completed

After 90 days of open-label etanercept, 51 responding children were randomized to continue etanercept or receive placebo in a double-blind comparison. The clinical primary endpoint, disease flare, was met in favor of etanercept (28% vs 81% with placebo; p=0.0030), but the randomized sample was small, limiting the strength of the evidence.

NCT00269867 · Phase 3 · completed

This randomised, double-blind, placebo-controlled trial in 428 patients with rheumatoid arthritis (ATTRACT) reported ACR20 responses of 50-58% across the infliximab plus methotrexate regimens against 20% on placebo plus methotrexate at week 30 (P<0.001 for each regimen), on a validated measure of disease activity.

NCT00317499 · Phase 3 · completed

Participants were randomized to etanercept or placebo with quadruple-blinding. Substantially more patients on etanercept achieved a meaningful joint-symptom response than on placebo, a highly significant difference.

NCT00106847 · Phase 3 · completed

This randomized, double-blind trial enrolled 683 patients and measured the proportion achieving at least 75% skin clearance (PASI 75), a standard psoriasis efficacy measure, at week 10. Infliximab produced clearance rates of 70-75% depending on dose, compared with 2% on placebo, a highly statistically significant difference.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

NCT00317499 · Phase 3 · completed

Participants were randomized to etanercept or placebo with quadruple-blinding. Substantially more patients on etanercept achieved a meaningful joint-symptom response than on placebo, a highly significant difference.

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.